Style | Citing Format |
---|---|
MLA | Shavandi M, et al.. "The Effect of Oral Administration of Silymarin on Serum Levels of Tumor Necrosis Factor-Α and Interleukin-1ß in Patients With Rheumatoid Arthritis." Iranian Journal of Immunology, vol. 19, no. 4, 2022, pp. 427-435. |
APA | Shavandi M, Yazdani Y, Asar S, Mohammadi A, Mohammadinoori E, Kiani A (2022). The Effect of Oral Administration of Silymarin on Serum Levels of Tumor Necrosis Factor-Α and Interleukin-1ß in Patients With Rheumatoid Arthritis. Iranian Journal of Immunology, 19(4), 427-435. |
Chicago | Shavandi M, Yazdani Y, Asar S, Mohammadi A, Mohammadinoori E, Kiani A. "The Effect of Oral Administration of Silymarin on Serum Levels of Tumor Necrosis Factor-Α and Interleukin-1ß in Patients With Rheumatoid Arthritis." Iranian Journal of Immunology 19, no. 4 (2022): 427-435. |
Harvard | Shavandi M et al. (2022) 'The Effect of Oral Administration of Silymarin on Serum Levels of Tumor Necrosis Factor-Α and Interleukin-1ß in Patients With Rheumatoid Arthritis', Iranian Journal of Immunology, 19(4), pp. 427-435. |
Vancouver | Shavandi M, Yazdani Y, Asar S, Mohammadi A, Mohammadinoori E, Kiani A. The Effect of Oral Administration of Silymarin on Serum Levels of Tumor Necrosis Factor-Α and Interleukin-1ß in Patients With Rheumatoid Arthritis. Iranian Journal of Immunology. 2022;19(4):427-435. |
BibTex | @article{ author = {Shavandi M and Yazdani Y and Asar S and Mohammadi A and Mohammadinoori E and Kiani A}, title = {The Effect of Oral Administration of Silymarin on Serum Levels of Tumor Necrosis Factor-Α and Interleukin-1ß in Patients With Rheumatoid Arthritis}, journal = {Iranian Journal of Immunology}, volume = {19}, number = {4}, pages = {427-435}, year = {2022} } |
RIS | TY - JOUR AU - Shavandi M AU - Yazdani Y AU - Asar S AU - Mohammadi A AU - Mohammadinoori E AU - Kiani A TI - The Effect of Oral Administration of Silymarin on Serum Levels of Tumor Necrosis Factor-Α and Interleukin-1ß in Patients With Rheumatoid Arthritis JO - Iranian Journal of Immunology VL - 19 IS - 4 SP - 427 EP - 435 PY - 2022 ER - |